Enhanced pulmonary accumulation of liposomal amphotericin B (AmBisome) in acute liver transplant failure

Journal of Antimicrobial Chemotherapy

Volumn 40, Issue 2, 1997, Pages 295-297

  Heinemann, V ^a   Bosse, D ^a   Jehn, U ^a   Debus, A ^a   Wachholz, K ^a   Forst, H ^b   Wilmanns, W ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b KLINIKUM AUGSBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT;

ADULT; ARTICLE; CASE REPORT; DRUG ACCUMULATION; DRUG BLOOD LEVEL; HUMAN; LIVER FAILURE; LIVER TRANSPLANTATION; MALE;

ACUTE DISEASE; AMPHOTERICIN B; ANTIBIOTICS, ANTIFUNGAL; FATAL OUTCOME; HUMANS; KIDNEY; LIPOSOMES; LIVER FAILURE; LIVER TRANSPLANTATION; LUNG; MALE; MIDDLE AGED;

EID: 0030770496     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/40.2.295     Document Type: Article

References (10)

1. Adler-Moore, J. P. & Proffitt, R. T. (1993). Development, characterization, efficacy and mode of action of AmBisome, a unilamellar liposomal formulation of amphotericin B. Journal of Liposome Research 3, 429-50.
2. Wang, L. H., Smith, P. C., Anderson, K. L. & Fielding, R. M. (1992). High-performance liquid chromatographic analysis of amphotericin B in plasma, blood, urine and tissues for pharmacokinetic and tissue distribution studies. Journal of Chromatography 579, 259-68.
3. Tollemar, J., Ringden, O. & Tyden, G. (1990). Liposomal amphotericin B (AmBisome) treatment in solid organ and bone marrow transplant recipients. Efficacy and safety evaluation. Clinical Transplantation 4, 167-75.
4. Meunier, F., Prentice, H. G. & Ringden, O. (1991). Liposomal amphotericin B (AmBisome): safety data from a phase II/III clinical trial. Journal of Antimicrobial Chemotherapy 28, Suppl. B, 83-91.
5. Tollemar, J., Ringden, O., Ricci, P., Tura, S., Meunier, F., Klastersky, J. et al. (1992). Early pharmacokinetic and clinical results from a noncomparative multicentre trial of amphotericin B encapsulated in small unilamellar liposome (AmBisome). Drug Investigation 4, 232-8.
6. Heinemann, V., Jehn, U., Scholz, P., Gleixner, B., Möhrle, W., Wachholz, K. et al. (1993). AmBisome - pharmacokinetics and clinical results. Bone Marrow Transplantation 12, Suppl. 4, S147-8.
7. Saba, T. M. (1970). Physiology and physiopathology of the reticuloendothelial system. Archives of Internal Medicine 126, 1031-52.
8. Kao, Y. J. & Juliano, R. L. (1981). Interactions of liposomes with the reticuloendothelial system. Biochemica et Biophysica Acta 677, 453-61.
9. Souhami, R. L., Patel, H. M. & Ryman, B. E. (1981). The effect of reticuloendothelial blockade on the blood clearance and tissue distribution of liposomes. Biochemica et Biophysica Acta 674, 354-71.
10. Dave, J. & Patel, H. M. (1986). Differentiation in hepatic and splenic phagocytic activity during reticuloendothelial blockade with cholesterol-free and cholesterol-rich liposomes. Biochemica et Biophysica Acta 888, 184-90.